Amylyx Pharmaceuticals (AMLX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Key program updates and clinical development

• Lead asset avexitide is a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), with phase III top-line results expected in Q3 following completion of enrollment in March.

• Five prior trials showed substantial reductions in hypoglycemia, supporting FDA Breakthrough Therapy designation.

• Phase III uses a 90 mg dose for improved day and night coverage, with robust study design and 90% power to detect a 35% relative difference in events.

• Primary endpoint is a composite of Level 2 and Level 3 hypoglycemic events, measured by finger stick and adjudicated by expert committee.

• Clinical quality emphasized through careful site selection, participant training, and real-time monitoring.

Market opportunity and commercialization plans

• PBH affects about 160,000 people in the U.S., with the population expected to grow as bariatric surgeries continue.

• No approved treatments exist; current standard is strict diet and off-label medications, with high unmet need and strong physician interest in new therapies.

• Commercial launch targeted for 2027, with infrastructure sized for rare disease and digital tools to broaden awareness.

• Pricing expected to align with premium orphan drugs in rare endocrine diseases, with payer engagement ongoing.

• Cash runway extends into 2028, covering all pre-commercial and launch activities.

Pipeline and strategic initiatives

• Developing a long-acting GLP-1 receptor antagonist (AMX0318) for once-weekly dosing, in IND-enabling studies with clinic entry targeted next year.

• Collaboration with Gubra leverages advanced peptide discovery and AI-driven candidate selection.

• Next-generation ALS therapy (AMX0114) targeting calpain-2 is in a multiple ascending dose study, with biomarker data to be presented soon.

• Intellectual property for avexitide extends to at least 2037, with potential for further extension and new claims.

• No significant competition in PBH space as other programs have been discontinued.